Matinas BioPharma Files 8-K on Security Holder Rights
Ticker: MTNB · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing
TL;DR
Matinas BioPharma 8-K: Changes to security holder rights and corporate docs filed 8/30.
AI Summary
Matinas BioPharma Holdings, Inc. filed an 8-K on August 30, 2024, reporting material modifications to security holder rights and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, with the date of the earliest event reported being August 30, 2024.
Why It Matters
This filing indicates potential changes affecting the rights of Matinas BioPharma's security holders and updates to the company's foundational documents.
Risk Assessment
Risk Level: low — The filing is procedural and informational, not indicating immediate financial distress or significant operational shifts.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- August 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38022 (identifier) — Commission File Number
- 46-3011414 (identifier) — IRS Employer ID Number
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not elaborated upon in the provided text snippet. Further review of the full filing would be necessary.
What amendments were made to Matinas BioPharma's articles of incorporation or bylaws?
The filing states that amendments to the articles of incorporation or bylaws were made, but the specific nature of these amendments is not detailed in the provided text.
What is the significance of filing financial statements and exhibits with this 8-K?
Filing financial statements and exhibits alongside the other items suggests these documents are relevant to the reported changes or provide necessary context for the modifications to security holder rights and corporate documents.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 30, 2024.
What is the principal executive office address for Matinas BioPharma Holdings, Inc.?
The principal executive offices of Matinas BioPharma Holdings, Inc. are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
Filing Stats: 1,008 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-09-03 08:56:28
Key Financial Figures
- $0.0001 — and outstanding shares of common stock, $0.0001 par value per share (the " Common Stock
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex3-1.htm (EX-3.1) — 9KB
- 0001493152-24-034729.txt ( ) — 232KB
- mtnb-20240830.xsd (EX-101.SCH) — 3KB
- mtnb-20240830_lab.xml (EX-101.LAB) — 33KB
- mtnb-20240830_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: September 3, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -4-